AUS
NZ
UK
CA
USA
IND
TrivarX Limited (ASX:TRI) has bolstered its leadership team by appointing Dr Danielle Meyrick as Chief Executive Officer and announced key clinical development milestones for its Stabl-Im stable isotope-enhanced MRI technology. The Perth-based biotech firm has secured investigational product supply, partnered with specialist CRO Beyond Drug Development, and aims to initiate its Phase 1 clinical trial in the second half of 2026. With $2.44 million in cash reserves as of 30 June 2026, TrivarX is well-positioned to advance the clinical development of its priority asset with a disciplined approach.
Key Points
- TrivarX Limited (ASX:TRI), a Perth-based biotechnology company focused on imaging and healthcare innovations, appointed Dr Danielle Meyrick as CEO effective 1 June 2026.
- The company secured investigational product supply after the quarter ended, eliminating a critical dependency for the Stabl-Im Phase 1 clinical trial.
- Engaged Beyond Drug Development as specialist CRO to assist with protocol design, regulatory filings, and clinical trial management.
- Plans to commence Phase 1 clinical feasibility study in H2 2026, pending regulatory, ethics, and operational approvals.
- Cash balance of $2.44 million as of 30 June 2026 supports near-term development activities.
- Refreshed development strategy emphasizes disciplined progression of Stabl-Im with limited near-term spending on mental health technologies.
Dr Danielle Meyrick Appointed CEO to Lead Clinical Development Efforts
On 1 June 2026, TrivarX appointed Dr Danielle Meyrick as Chief Executive Officer, enhancing the company’s clinical and regulatory leadership capabilities. Dr Meyrick brings over 20 years of international experience as a medical doctor, radiopharmaceutical chemist, and biotech executive, specializing in clinical medicine, drug development, radiotheranostics, and isotope-based technologies. Her leadership aligns with TrivarX’s transition to clinical-stage development and accelerates evidence generation for its lead asset.
Before joining TrivarX, Dr Meyrick held senior roles including Chief Medical Officer (APAC) at Telix Pharmaceuticals (ASX:TLX), Chief Medical Officer at ITM Isotope Technologies Munich, and Chief Scientific Officer at GenesisCare CRO. Her expertise covers clinical strategy, regulatory engagement with FDA, EMA, and TGA, trial design and execution, and advancing diagnostic and therapeutic technologies from early stages through commercialization. Since her appointment, she has initiated implementation of TrivarX’s clinical development strategy and engaged specialist partners.
Stabl-Im Stable Isotope MRI Platform Progresses Toward Phase 1 Clinical Trial
TrivarX’s immediate development focus is Stabl-Im, a stable isotope-enhanced MRI platform for clinical imaging applications. The planned Phase 1 clinical feasibility study will assess safety and tolerability of controlled D2O total body water enrichment and characterize enrichment kinetics in healthy volunteers. Following this, an expansion cohort will evaluate feasibility and preliminary imaging performance in oncology.
The Phase 1 study is targeted to start in the second half of 2026, subject to regulatory, ethics, site, and operational approvals. Securing investigational product supply after quarter-end removed a key risk to the trial timeline. This milestone marks the company’s transition from preclinical to clinical validation and advances Stabl-Im toward broader clinical development and potential commercialization.
Beyond Drug Development Engaged to Support Clinical Trial Execution
TrivarX has engaged Beyond Drug Development, a specialist early-phase clinical CRO, to assist with Phase 1 protocol development, regulatory documentation, and trial execution. Beyond brings expertise in regulatory strategy, clinical operations, and imaging product development. This partnership reflects TrivarX’s strategy to leverage external expertise to accelerate clinical timelines. Financial terms of the engagement were not disclosed.
Beyond Drug Development supports protocol finalization, regulatory submissions, clinical site engagement, and operational planning including formulation and supply. This collaboration underscores TrivarX’s disciplined clinical approach and recognition of the specialized requirements for early-phase imaging trials, aiming to maximize execution quality and regulatory compliance.
Investigational Product Supply Secured, Removing Trial Initiation Risk
Following the quarter’s end, TrivarX secured the investigational product supply necessary to commence the Stabl-Im Phase 1 trial, a critical enabling milestone. This procurement alleviates a previously identified risk that could have delayed trial start. The company remains focused on completing remaining clinical, regulatory, and operational tasks ahead of the planned H2 2026 trial launch.
Ensuring investigational product availability is often complex, involving technical, regulatory, and operational coordination. TrivarX’s confirmation of supply enhances investor confidence in meeting the Phase 1 trial timeline and reflects progress from supply uncertainty to a secured position.
Refreshed Development Strategy Prioritizes Capital Efficiency and Clinical Execution
Following Dr Meyrick’s appointment, TrivarX conducted a structured review of its development strategy, resulting in a renewed focus on disciplined clinical execution and strategic capital allocation. Near-term resources will concentrate on advancing Stabl-Im, with expenditures aligned to generating meaningful clinical and scientific evidence and shareholder value. This represents a strategic narrowing from the company’s previous broader portfolio approach.
The company is also exploring opportunities to expand the Stabl-Im pipeline in scientifically credible and strategically aligned clinical areas that offer clear value creation pathways. This disciplined strategy appeals to investors seeking reduced execution risk and clearer milestones.
Mental Health Technology Assets Temporarily Deprioritized Amid Clinical Focus
TrivarX holds intellectual property related to mental health technologies developed previously. As the company prioritizes Stabl-Im clinical activities, spending on mental health technologies will be limited mainly to maintaining IP positions. This deliberate deprioritization allows resource concentration on Stabl-Im’s clinical advancement while preserving optionality for future value realization through partnerships, licensing, or strategic transactions.
This approach reflects the resource constraints typical of clinical-stage biotech firms and a strategic choice to focus on the most commercially promising near-term asset. TrivarX continues to evaluate development potential and value maximization options for its mental health assets.
Strong Cash Position Supports Near-Term Clinical Milestones
As of 30 June 2026, TrivarX held $2.44 million in cash, providing funding for planned near-term development activities. While the company did not disclose burn rate or runway, this cash position is critical to advancing the Phase 1 trial scheduled for H2 2026. Investors should monitor future updates for cash flow details and any capital raising or partnership developments.
The company’s capital position and development timeline are closely linked. Successful clinical progress may facilitate future funding access, while delays could increase reliance on existing cash reserves.
Active Market Engagement and Investor Communication During Transition
During the quarter, TrivarX enhanced engagement with existing and potential investors. Newly appointed CEO Dr Danielle Meyrick presented at the JP Equity Partners 'Boom of the Biotech II' investor event, outlining the company’s strategy, Stabl-Im’s clinical and commercial potential, and near-term development plans. This engagement reflects TrivarX’s commitment to transparent communication as it approaches key clinical milestones.
Comprehensive Clinical Preparation Progressing Across Multiple Workstreams
TrivarX advanced multiple clinical preparation activities during the quarter, including protocol development, regulatory documentation, site engagement, formulation, and clinical start-up processes. While specific timelines were not provided, the company remains focused on completing these tasks ahead of the planned H2 2026 trial start.
The coordination of these workstreams is essential for trial initiation, with upcoming milestones including regulatory and ethics approvals and site activations necessary before patient enrollment.
Clear Pathway to Phase 1 Trial Initiation Targeted for Second Half of 2026
TrivarX aims to finalize the Stabl-Im Phase 1 protocol, regulatory and ethics submissions, and investigational product formulation and testing in the coming quarters. Pending successful completion of these prerequisites, the company targets commencing the Phase 1 clinical program in H2 2026—a significant milestone marking clinical development progress.
The appointment of Dr Meyrick, engagement of Beyond Drug Development, and secured investigational product supply collectively support the feasibility of this timeline. Investors will closely watch upcoming updates for progress on protocol completion, regulatory approvals, and site readiness. Any delays or changes to the Phase 1 start date would be material to the investment community.
